{"organizations": [], "uuid": "fb551f5473606f111bfc469056e74d3844115781", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180501.html", "section_title": "Archive News &amp; Video for Tuesday, 01 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-regeneron-and-sanofi-to-lower-net/brief-regeneron-and-sanofi-to-lower-net-price-of-praluent-for-express-scripts-patients-idUSFWN1S808G", "country": "US", "domain_rank": 408, "title": "BRIEF-Regeneron And Sanofi To Lower Net Price Of Praluent For Express Scripts Patients", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.987, "site_type": "news", "published": "2018-05-01T19:26:00.000+03:00", "replies_count": 0, "uuid": "fb551f5473606f111bfc469056e74d3844115781"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-regeneron-and-sanofi-to-lower-net/brief-regeneron-and-sanofi-to-lower-net-price-of-praluent-for-express-scripts-patients-idUSFWN1S808G", "ord_in_thread": 0, "title": "BRIEF-Regeneron And Sanofi To Lower Net Price Of Praluent For Express Scripts Patients", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "regeneron", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "regeneron pharmaceuticals inc", "sentiment": "negative"}, {"name": "sanofi", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "regeneron pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1 (Reuters) - Regeneron Pharmaceuticals Inc:\n* REGENERON AND SANOFI TO LOWER NET PRICE OF PRALUENTÂ® (ALIROCUMAB) INJECTION IN EXCHANGE FOR STRAIGHTFORWARD, MORE AFFORDABLE PATIENT ACCESS FOR EXPRESS SCRIPTS PATIENTS\n* REGENERON PHARMACEUTICALS - EXPRESS SCRIPTS HAS SELECTED PRALUENT AS EXCLUSIVE PCSK9 INHIBITOR THERAPY ON ITS NATIONAL PREFERRED FORMULARY AS OF JULY 1\n* REGENERON PHARMACEUTICALS INC - EXPRESS SCRIPTS TO PASS ON SAVINGS TO ELIGIBLE PATIENTS FROM PARTICIPATING COMMERCIAL HEALTH PLANS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-01T19:26:00.000+03:00", "crawled": "2018-05-02T16:07:59.008+03:00", "highlightTitle": ""}